Polynovo Limited · ASX:PNV
Polynovo — Investor Presentation (November 2015)
24 slides from Polynovo's investor presentation, Nov 16, 2015
Slide 1: Investor Presentation
PolyNovo Limited ABN 96 083 866 862 2/320 Lorimer Street, Port Melbourne VIC 3207 Tel: +61 3 8681 4050 Fax: +61 3 8681 4099 For personal use only 16 November 2015 Investor Presentation PolyNovo Limited (ASX:PNV) has released an updated investor presentation for shareholders, fund managers and other
Slide 2: PolyNovo
For personal use only PolyNovo We regenerate lost or damaged tissue through patented biodegradable medical devices.
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been prepared by PolyNovo Limited (PolyNovo) and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, represent
Slide 4: Executive Summary
Executive Summary For personal use only 1. PolyNovo is the developer and manufacturer of patented biodegradable polymer medical devices 2. The devices are made of our biodegradable polymer, NovoSorb™. The first commercial applications are in a foam-based dermal matrix and wound scaffold for regenera
Slide 5: Agenda
Agenda For personal use only o Corporate overview o The product: Biodegradable Temporising Matrix (BTM) o Product pipeline and applications o Path to market and 2016 work-plan o Board and senior executive team 4
Slide 6: Corporate Overview
Corporate Overview For personal use only $A Key Milestones ASX Code PNV 2004 PolyNovo incorporated (ex-CSIRO) Share Price 16 cents (close 13/11/15) 2006 NovoSkin feasibility study Issued Shares 419.5 million 2008 Port Melbourne facility established Market Cap. $67.12 million 2010 NovoSkin is incorpo
Slide 7: The product: NovoSorb and its Uniqueness
The product: NovoSorb and its Uniqueness For personal use only NovoSorb is a patented biodegradable polymer that can be utilised as: o a foam wound scaffold o a thermoplastic extrusion o a filaments for weaving or knitting o a solution for spray or dip coatings of other devices Purely synthetic BTM
Slide 8: Biodegradable Temporising Matrix (BTM)
Biodegradable Temporising Matrix (BTM) For personal use only o Regenerates a new dermis o Superior cosmetic and functional outcomes in wounds, burns and reconstruction repair o Patented technology developed by CSIRO o Excellent safety profile o Significant trade secrets in production and difficult t
Slide 9: How the BTM works
How the BTM works For personal use only Full Thickness Burns and Surgical Wounds BTM in full thickness burn post surgical debridement. 1 The wound is ‘physiologically closed’ limiting contraction and the risk of infection. BTM fully integrated The sealing membrane can be removed when donor sites are
Slide 10: BTM in use
BTM in use For personal use only Current standard of care BTM - Innovates the standard o Note the scarring and the tendons in this example of the traditional approach o Note tendons and o Note the lack of scar/contracture and topography. poor skin quality 4 9
Slide 11: In use: Tendon moves freely
In use: Tendon moves freely For personal use only Video https://www.youtube.com/channel/UCL-B7V8ImJxqDmKiHpmY-TA 10
Slide 12: In use: Debrided forearm ready for BTM
In use: Debrided forearm ready for BTM For personal use only 11
Slide 13: In use: BTM Implanted (Day 0)
In use: BTM Implanted (Day 0) For personal use only o Full coverage of the arm o Cut and contoured to fingers o Staples retain BTM in position 12
Slide 14: In use: Before Delamination of BTM (Day 33)
In use: Before Delamination of BTM (Day 33) For personal use only BTM achieves full cellular integration NB: Silver on the external film is from Acticoat™ and antimicrobial protective dressing. 13
Slide 15: In use: Delamination of the BTM (Day 33)
In use: Delamination of the BTM (Day 33) For personal use only Key advantages: o Neo-dermis regenerated o Quality and elasticity of the new tissue o No “pie dish” effect o One piece easy removal Video https://www.youtube.com/channel/UCL-B7V8ImJxqDmKiHpmY-TA 14
Slide 16: In use: Forearm with Split Skin Graft
In use: Forearm with Split Skin Graft For personal use only BTM has regenerated the dermis shown in the even pink colour and SSG closure (in operating room). 15
Slide 17: In use: Healed Forearm (Day 180)
In use: Healed Forearm (Day 180) For personal use only BTM’s key competitive advantages Lack of scar and skin contraction o Results in smooth and “full” nature of the healed forearm o Minimal “diamond” effect from the SSG mesh o Smooth and normal cosmetic appearance o Fully functional arm o Note: in
Slide 18: Product Pipeline and Regulatory Approvals
Product Pipeline and Regulatory Approvals For personal use only Product Application Market Size Commercial Status 1st Regulatory US$ Approval Expected NovoPore Negative pressure wound ~$450m of foam and Discussions with multinationals building Now have CE & FDA 510(k) therapy (NPWT) gauze component
Slide 19: Projected Developments and Markets
Projected Developments and Markets For personal use only Opportunities further out Stem cell and organ tissue Coatings/ regeneration within the Antimicrobials polymer 2018 Bladder Bone Void Filler $1B + market 2021/22 $2.3B market 2020/21 Breast $2B market 2018 Hernia ~$1B market 2018 Current focus
Slide 20: Market Projections and 2016 Work-plan
Market Projections and 2016 Work-plan For personal use only Path to revenues starting 2016 o Income from H2 through BTM sign-up rights and sales o Europe sales expected to commences 2018 o Further milestone and sign-up payments each region o Hernia and breast sling anticipated to reach FDA 510(k) fi
Slide 21: Board and Senior Executives
Board and Senior Executives For personal use only David Williams – Chairman An experienced Director and Investment Banker with a proven track record in business development and strategy, as well as in corporate initiatives specialising in mergers and acquisitions and capital raisings. He possesses o
Slide 22: Board and Senior Executives (continued)
Board and Senior Executives (continued) For personal use only Philip Powell – Non Executive Director Over 15 years experience in investment banking specialising in capital raisings, IPOs, mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors in
Slide 23: Capabilities and Team
Capabilities and Team Key Staff currently 10 FTE increasing to 14 FTE For personal use only o 2 Full-time Regulatory Managers o 2 Full-time Development Scientist o 1 Full-time USA-based contractor Project Manager for BARDA o 1 Full-time Quality Manager o 2 Production staff o Office & administrative
Slide 24: For personal use only
For personal use only 2/320 Lorimer St, Port Melbourne Vic 3207 Follow us: